Please use this identifier to cite or link to this item:
|Title:||Proteomics-related biomarkers for HBV-associated hepatocellular carcinoma : current status and future prospects||Authors:||Sadrolodabaee, Laleh
Tan, Jane YL.
Chen, William Wei Ning
|Issue Date:||2012||Source:||Feng, H., Zhang, J., Tan, J. YL., Sadrolodabaee, L., & Chen, W. N. W. (2012). Proteomics-related biomarkers for HBV-associated hepatocellular carcinoma : current status and future prospects. Future virology, 7(2), 161-171.||Series/Report no.:||Future virology||Abstract:||HBV infection is the major cause of the development of hepatocellular carcinoma (HCC). HCC is one of the most common malignancies in the world. The morbidity rate associated with HCC is mainly linked to late diagnosis. Thus, it is very important to discover prognostic factors that can act as biomarkers for preventing HCC development, and those that can act as therapeutic targets. Proteomics analysis has been applied to identify biomarkers from clinical HCC samples. In addition, the cell-based HBV replication and viral protein overexpression system, which provides a model of the cell at an early stage of viral infection, was also used to identify biomarkers. The proteins identified at this stage may be relevant to HBV-associated HCC prognosis. In this review, we discuss the current status of proteomics analysis in the discovery of cellular proteins and prognostic HCC biomarkers, with a special focus on cell metastasis and angiogenesis.||URI:||https://hdl.handle.net/10356/100039
|DOI:||10.2217/fvl.11.148||Schools:||School of Chemical and Biomedical Engineering||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||SCBE Journal Articles|
Updated on May 29, 2023
Web of ScienceTM
Updated on Jun 1, 2023
Page view(s) 10793
Updated on Jun 8, 2023
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.